- |||||||||| Journal, Combination therapy: Research Progress in the Use of Small Molecule Smac Mimetics in Combination Therapy of Cancer. (Pubmed Central) - May 20, 2024
According to the phase II clinical data, xevinapant has the potential to significantly enhance the standard therapy for patients with head and neck cancer, which is expected to be approved as an innovative therapy for cancer patients. Therefore, this paper briefly describes the mechanism of IAPs (AT-406, APG-1387, GDC- 0152, TL32711, and LCL161) as single or in combination for cancer treatment, their application status as well as the synthetic pathway, and explores the research prospects and challenges of IAPs antagonists in the tumor combination therapy, with the hope of providing strong insights into the further development of Smac mimics in tumor therapy.
- |||||||||| APG-1387 / Ascentage Pharma
Trial completion date, Trial primary completion date, Metastases: APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 29, 2024
P1/2, N=44, Recruiting,
Therefore, this paper briefly describes the mechanism of IAPs (AT-406, APG-1387, GDC- 0152, TL32711, and LCL161) as single or in combination for cancer treatment, their application status as well as the synthetic pathway, and explores the research prospects and challenges of IAPs antagonists in the tumor combination therapy, with the hope of providing strong insights into the further development of Smac mimics in tumor therapy. Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- |||||||||| APG-1387 / Ascentage Pharma
Trial completion date, Trial primary completion date, Metastases: APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 8, 2023
P1/2, N=44, Recruiting,
Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Jun 2024 Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Feb 2024
- |||||||||| APG-1387 / Ascentage Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies (clinicaltrials.gov) - Aug 16, 2022
P1, N=90, Recruiting,
These preliminary safety and efficacy data support continued development of APG-1387 in combination with other agents towards a functional cure of chronic HBV infection. Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Mar 2021 --> Oct 2022
- |||||||||| APG-1387 / Ascentage Pharma
Journal: Targeting cIAPs attenuates CCl-induced liver fibrosis by increasing MMP9 expression derived from neutrophils. (Pubmed Central) - Jan 12, 2022
Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Mar 2021 --> Oct 2022 These results suggested that cIAPs, especially cIAP2, might play a novel role in the pathogenesis of liver fibrosis, and targeting cIAPs represented a promising therapeutic strategy for liver fibrosis by increasing MMP9 expression induced by CCL5 chemotactic neutrophils.
- |||||||||| APG-1387 / Ascentage Pharma
Trial completion: APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B (clinicaltrials.gov) - Nov 8, 2021
P1, N=49, Completed,
These results suggested that cIAPs, especially cIAP2, might play a novel role in the pathogenesis of liver fibrosis, and targeting cIAPs represented a promising therapeutic strategy for liver fibrosis by increasing MMP9 expression induced by CCL5 chemotactic neutrophils. Active, not recruiting --> Completed
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie
Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5010;
Only in the triple combination group, cIAP1, cIAP2, and XIAP as well as MDM2 were largely diminished and p21 was marked decreased. In conclusion, our study demonstrates that co-targeting intrinsic and extrinsic apoptosis maximizes cell death induction in AML cells with acquired resistance to VEN or with TP53 deletion/mutations by antagonizing Bcl-2, eliminating cIAPs and XIAP, as well as MDM2 and p21, a finding that needs to be validated clinically.
- |||||||||| APG-1387 / Ascentage Pharma
Enrollment closed: APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B (clinicaltrials.gov) - Jul 26, 2021
P1, N=49, Active, not recruiting,
In conclusion, our study demonstrates that co-targeting intrinsic and extrinsic apoptosis maximizes cell death induction in AML cells with acquired resistance to VEN or with TP53 deletion/mutations by antagonizing Bcl-2, eliminating cIAPs and XIAP, as well as MDM2 and p21, a finding that needs to be validated clinically. Recruiting --> Active, not recruiting
- |||||||||| APG-1387 / Ascentage Pharma
Enrollment open, Trial initiation date, Metastases: APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 29, 2021
P1/2, N=44, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2020 --> Mar 2021
- |||||||||| APG-1387 / Ascentage Pharma
Enrollment open, Trial initiation date, Combination therapy: A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B (clinicaltrials.gov) - Oct 12, 2020
P2, N=122, Recruiting,
In summary, our results suggest great potential of combination therapy with APG-1387 and CTB-006 for solid tumor therapy and deserves further clinical investigation. Not yet recruiting --> Recruiting | Initiation date: Oct 2020 --> Jun 2020
- |||||||||| APG-1387 / Ascentage Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies (clinicaltrials.gov) - Aug 8, 2020
P1, N=90, Recruiting,
Not yet recruiting --> Recruiting | Initiation date: Oct 2020 --> Jun 2020 Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Sep 2020 --> Mar 2021
- |||||||||| [VIRTUAL] Ascentage Pharma Group () - Jun 9, 2020 - Abstract #BIO2020BIO_109;
The company was listed on Hong Kong Stock Exchange in Oct., 2019. We seek global or region partners to co-develop/commercialize our assets.
- |||||||||| APG-1387 / Ascentage Pharma
Enrollment open, Combination therapy, Metastases: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors (clinicaltrials.gov) - May 21, 2020
P1/2, N=108, Recruiting,
Application of IAP antagonist might represent a novel immunotherapeutic strategy for HBV functional cure. Not yet recruiting --> Recruiting
- |||||||||| APG-1387 / Ascentage Pharma
Therapeutic potential of IAP inhibitor APG-1387 in combination with PARP- or MEK-targeted therapy, or chemotherapy in pancreatic cancer (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2740;
The molecular mechanisms underlying the synergy are currently being investigated.In summary, our results suggest that APG-1387 is a potential agent for pancreatic cancer treatment, ascribing to its potential synergistic antitumor effect by combining with either PARP inhibitors in BRCA1/2 mutant or MEK inhibitors in KRAS mutant pancreatic cancers. Overall, our data provide the scientific rationale for the future clinical development of these combinations in pancreatic cancer patients with distinct genomic alterations.
- |||||||||| APG-1387 / Ascentage Pharma
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B (clinicaltrials.gov) - May 15, 2020
P1, N=60, Recruiting,
Overall, our data provide the scientific rationale for the future clinical development of these combinations in pancreatic cancer patients with distinct genomic alterations. Active, not recruiting --> Recruiting | N=30 --> 60 | Trial completion date: Feb 2020 --> Oct 2021 | Trial primary completion date: Feb 2020 --> Oct 2021
- |||||||||| APG-1387 / Ascentage Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies (clinicaltrials.gov) - Mar 30, 2020
P1/2, N=90, Recruiting,
Phase classification: P1/2 --> P1 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Sep 2020
- |||||||||| APG-1387 / Ascentage Pharma
Trial primary completion date, Combination therapy, Metastases: APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies (clinicaltrials.gov) - Jul 5, 2019
P1/2, N=90, Recruiting,
Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Sep 2019 --> Feb 2020 Trial primary completion date: Jun 2019 --> Dec 2019
|
